生物医药

肿瘤分子靶向治疗药物，抗体药物，抗体偶联药物

1. Zhou DD, Zhai XT, Zhang LW, Xie ZH, Wang Y, Zhen YS, Gao RJ*, Miao QF*. A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers.NPJ PrecisOncol. 2024 Apr 23;8(1):94.
2. Zhou DD, Sun LP, Yu Q, Zhai XT, Zhang LW, Gao RJ, Zhen YS, Wang R, Miao QF*. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2. Int J Biol Macromol. 2023 Dec 31;253(Pt 6):127105.
3. Sun LP, Bai WQ, Zhou DD, Wu XF, Zhang LW, Cui AL, Xie ZH, Gao RJ, Zhen YS, Li ZR*, Miao QF*. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. J Med Chem. 2023 Nov 9;66(21):14700-14715.
4. Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, Zhou D, Wang R, Gong J, Miao Q*, Kang L*, Yang J*.Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):168-183.
5. Wang YY, Li L, Liu XJ, Miao QF*, Li Y, Zhang MR, Zhen YS*. Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer. J Pharm Anal. 2022 Apr;12(2):232-242.
6. Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, Miao QF. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Mil Med Res. 2021 Dec 9;8(1):63.
7. Gong J, Guo F, Cheng W, Fan H, Miao Q*, Yang J*. Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models. Artif Cells Nanomed Biotechnol. 2020;48(1):408-414.
8. Wang R, Li L, Duan A, Li Y, Liu X, Miao Q*, Gong J*, Zhen Y. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.Cancer Lett. 2019 ; 448:84-93.
9. Wang R, Li L, Zhang S, Li Y, Wang X, Miao Q*, Zhen Y.A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas. Mol Oncol. 2018;12(3):339-355.
10. Hu XY, Wang R, Jin J, Liu XJ, Cui AL, Sun LQ, Li YP, Li Y, Wang YC, Zhen YS, Miao QF*, Li ZR*. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Mol Oncol. 2019;13(2):246-263.

1. 抗CD30抗体与力达霉素的抗体药物偶联物、制备方法及其用途。专利号：ZL201710242977.8。
2. 一种靶向于EGFR的抗体偶联药物及其制备方法和其用途。专利号：ZL201811245835.8。
3. 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法。专利号：ZL201710718048.X。
4. 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法。专利号：ZL200910157388.5。
5. 一种双单链抗体强化融合蛋白dFv－LDP－AE及其制备方法和应用。专利号：ZL200910000300.9。
6.一种针对Trop2的单克隆抗体及其应用。申请号：202210864288.1；PCT/CN2023/108534。
7.一种针对间皮素的抗体及应用。申请号：202320023877.1。
8.一种靶向TROP2的抗体-药物偶联物及其制备方法和其用途。申请号：202311325627X。

技术咨询